ASX
LCT 0.038    Last updated 11.46 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

LCT’s lead product NTCELL® is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration.

 

The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson’s disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson’s disease. It has the potential to be used in a number of other central nervous system indications such as Huntington’s, Alzheimer’s and motor neurone diseases.

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. 

 

LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.

 

— 28 August 2015

LCT to receive Callaghan Innovation Growth Grant

Living Cell Technologies Limited is to receive a Callaghan Innovation R&D Growth Grant. The company’s application for a grant of an estimated $2m has been approved. The amount received will reimburse Living Cell Technologies for 20 percent of actual eligible New Zealand research and development expenditure over the next three years.

Read More Read Less

— 19 August 2015

Preliminary Final Report 30 June 2015

Living Cell Technologies Limited today announced the Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2015.

Read More Read Less
Load More

— 8 May 2014

Please refer to our news releases

Load More
— 12 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
Announcements

— 28 August 2015

LCT to receive Callaghan Innovation Growth Grant

Living Cell Technologies Limited is to receive a Callaghan Innovation R&D Growth Grant. The company’s application for a grant of an estimated $2m has been approved. The amount received will reimburse Living Cell Technologies for 20 percent of actual eligible New Zealand research and development expenditure over the next three years.

Read More Read Less

— 19 August 2015

Preliminary Final Report 30 June 2015

Living Cell Technologies Limited today announced the Preliminary Final Report (Appendix 4E) on the results for the year ended 30 June 2015.

Read More Read Less
Load More
LCT in the News

— 8 May 2014

Please refer to our news releases

Load More
Events
— 12 November 2015

LCT Annual General Meeting. To be held in Auckland, New Zealand.

Load More
© 2015 Living Cell Technologies Limited.
site by { brownpaperbag }